Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus

Six Indications Vs. Prior Plan For 10 By End Of Year

 
• By Mandy Jackson
  
Roivant boosts its oversight of Immunovant as the latter executes its IMVT-1402 strategy (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Scrip